FDA panel narrowly backs COVID-19 pill from Merck

A panel of U.S. health advisers narrowly backed a closely watched COVID-19 pill from Merck. The FDA panel voted 13-10 that the antiviral drug’s benefits outweigh its risks, including potential birth defects if used during pregnancy. (Dec. 1)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting